Ascend Advanced Therapies vs ReciBioPharm: CDMO Comparison
How does Ascend Advanced Therapies compare to ReciBioPharm for AAV manufacturing?
Side-by-side comparison of Ascend Advanced Therapies and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Ascend Advanced Therapies holds 1 active EMA GMP certificates; ReciBioPharm does not appear in EudraGMDP.
- ReciBioPharm maintains 3 MHRA / UK GMP certificates; Ascend Advanced Therapies does not.
On a 13-modality CDMO landscape, both Ascend Advanced Therapies and ReciBioPharm qualify as AAV manufacturers; ReciBioPharm carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Ascend Advanced Therapies and ReciBioPharm qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Ascend Advanced Therapies vs ReciBioPharm
How does Ascend Advanced Therapies compare to ReciBioPharm for AAV manufacturing?
On CDMO Signal's composite Signal Score, Ascend Advanced Therapies is 78/100 and ReciBioPharm is 83/100; European coverage is 1 active EMA+MHRA certificate for Ascend Advanced Therapies vs 3 for ReciBioPharm. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
How do Ascend Advanced Therapies and ReciBioPharm compare on European GMP coverage?
Ascend Advanced Therapies holds 1 active EMA GMP certificate and 0 MHRA / UK certificates. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — Ascend Advanced Therapies or ReciBioPharm?
Both Ascend Advanced Therapies and ReciBioPharm are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Ascend Advanced Therapies carries a Signal Score of 78/100 and ReciBioPharm carries 83/100 — essentially tied for ReciBioPharm. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →